Article Details

Are BioPharma companies the next big tariffs victim? - Morningstar Australia

Retrieved on: 2025-04-14 02:22:34

Tags for this article:

Click the tags to see associated articles and topics

Are BioPharma companies the next big tariffs victim? - Morningstar Australia. View article details on hiswai:

Summary

The article discusses depreciation costs and US-branded drug sales impacting biopharma financials. These factors, alongside tariffs, influence financial ratios, gross margins, and operating margins, linking to management accounting and corporate finance in biopharma.

Article found on: www.morningstar.com.au

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up